Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.441 +0.091 (+3.88%)
Streaming Delayed Price Updated: 1:40 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Acumen (ABOS) Q1 2026 Earnings Transcript ↗
Acumen (ABOS) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Acumen Pharmaceuticals Q1 Earnings Call Highlights ↗
Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader... 
Via MarketBeat
Topics Earnings
Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms ↗
Via Chartmill
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Acumen Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
A Preview Of Acumen Pharmaceuticals's Earnings ↗
 
Via Benzinga
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗
Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027. 
Via Chartmill
Topics Earnings
News headline image
Preview: Acumen Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million. 
Via Benzinga
News headline image
Preview: Acumen Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Acumen Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Acumen Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 ↗
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 ↗
ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 ↗
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 26, 2024 ↗
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
News headline image
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot ↗
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding. 
Via InvestorPlace
News headline image
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom ↗
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population. 
Via InvestorPlace
News headline image
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.